Our findings illustrate that germline cancer gene panel testing should be considered in specific patients with a co‐occurrence of breast cancer and NET and these panels should include MEN1 and other hereditary cancer syndrome genes. This evidence concerns the gene MEN1 and Inherited cancer-predisposing syndrome.